B.1.617 Variant

US vaccine maker Pfizer has sought a fast-track approval for its COVID-19 vaccine from the Centre claiming that it is 'highly effective' against the B.1.617 variant in India. Besides, the company also assured that its vaccine is suitable for everyone above age 12 and can be stored for one month at 2-8 degrees. This comes after Pfizer proposed 5-crore doses to India with certain relaxations earlier this week.